MC2 25
Alternative Names: MC2 25 cream; MC2-25; MC2-25 PAD™ Cream; MC2-25 VLSLatest Information Update: 02 Dec 2024
At a glance
- Originator MC2 Therapeutics
- Class Antipruritics; Dipeptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pruritus; Vulvar lichen sclerosus
Most Recent Events
- 08 Nov 2024 MC2 Therapeutics completes phase-II clinical trials in Vulval-lichen-sclerosis in Denmark (Topical) (NCT06132919)
- 02 Feb 2024 MC2 Therapeutics completes the phase-II ITCHINESS clinical trials in Pruritus in Germany, Hungary, Poland, United Kingdom (Topical) (ISRCTN74524864)
- 07 Dec 2023 MC2 Therapeutics completes enrolment in its phase-II clinical trials in Pruritus in Germany, Hungary, Poland, United Kingdom (Topical) (ISRCTN74524864)